News | Heart Failure | November 13, 2017

Moderna and AstraZeneca to Co-Develop, Commercialize Relaxin mRNA Therapeutic for Heart Failure

Pharmaceutical would instruct cells to produce and express Relaxin hormone to impact underlying conditions that exacerbate heart failure

November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize a messenger RNA (mRNA) therapeutic encoding for Relaxin. The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.

Heart failure occurs when the heart is weakened and cannot pump enough blood to meet the body’s needs. AZD7970 is being developed to instruct cells in the body to produce and express Relaxin, a secreted protein with systemic effect. Biologic functions for Relaxin suggest that expression of the hormone may directly impact underlying conditions that exacerbate heart failure, leading to the regrowth of heart tissue, controlling inflammation, reordering the extracellular matrix, improving renal function and relieving hepatic portal pressure. AZD7970 utilizes one of Moderna’s proprietary formulations, N2GL, which enables systemic, repeat dosing of mRNA therapeutics.

Approximately 5.7 million adults in the U.S. alone have heart failure. About half of those who develop heart failure die within five years of being diagnosed. A global health burden, heart failure impacts approximately 26 million people around the world.

Under the terms of the new agreement between the companies, Moderna will fund and be responsible for preclinical development of AZD7970, including the conduct of Good Laboratory Practice (GLP) toxicology studies. AstraZeneca will be responsible for early clinical development of AZD7970, and Moderna and AstraZeneca will share the costs of late-stage clinical development. Moderna and AstraZeneca will co-commercialize AZD7970 in the U.S. under a 50:50 profit sharing arrangement. AstraZeneca will lead ex-U.S. commercialization efforts, with Moderna receiving tiered royalties up to substantial double digits on ex-U.S. sales.

This marks the second strategic agreement between Moderna and AstraZeneca to advance mRNA therapeutics in the cardiometabolic space. The lead program from the first strategic agreement, which was announced in 2013, is AZD8601, a localized mRNA therapeutic that encodes for vascular endothelial growth factor (VEGF-A). AZD8601 has successfully completed a Phase 1 study, and AstraZeneca has submitted a Clinical Trial Application (CTA) in Europe to initiate a Phase 2a study of AZD8601 in heart failure patients undergoing cardiac bypass grafting (CABG) surgery.

For more information: www.modernatx.com, www.astrazeneca.com

Related Content

Feature | Heart Failure | February 20, 2020 | Dave Fornell, Editor
There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this comp
he U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption (IDE) application to start a U.S. early feasibility study (EFS) of its total artificial heart.
News | Heart Failure | February 12, 2020
February 12, 2020 — The U.S.
 Revivant TC
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less
 impulse dynamics Optimizer for Heart failure.
News | Heart Failure | December 12, 2019
December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System
The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA
News | Heart Failure | November 21, 2019
November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment
Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019
November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of
The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
Overlay Init